Two Sigma Securities’s ADMA Biologics ADMA Stock Holding History

Two Sigma Securities’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-16,994	Closed	-$153K	–	1683
2026 Q1	$153K	Buy	+16,994	New	+$268K	0.02%	1103
2025 Q3	–	Sell	-11,457	Closed	-$209K	–	1337
2025 Q2	$209K	Buy	+11,457	New	+$234K	0.03%	901
2023 Q4	–	Sell	-18,097	Closed	-$64.8K	–	2971
2023 Q3	$64.8K	Buy	18,097 +4,827	+36%	+$18.6K	﹤0.01%	2443
2023 Q2	$49K	Buy	+13,270	New	+$49.2K	﹤0.01%	2395
2023 Q1	–	Sell	-19,440	Closed	-$75.4K	–	2584
2022 Q4	$75.4K	Sell	19,440 -67,875	-78%	-$209K	﹤0.01%	2110
2022 Q3	$212K	Buy	+87,315	New	+$209K	0.01%	1902
2022 Q2	–	Sell	-11,184	Closed	-$20K	–	2164
2022 Q1	$20K	Sell	11,184 -10,320	-48%	-$16.1K	﹤0.01%	1978
2021 Q4	$30K	Buy	+21,504	New	+$28.3K	﹤0.01%	1357

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Securities's ADMA Position: Q2 2026 in Review

Two Sigma Securities sold out of ADMA Biologics (ADMA) in Q2 2026, closing a stake of 16,994 shares — an estimated $153K sold.

Two Sigma Securities first reported a position in ADMA in Q4 2021 and held it in 8 quarters. The position peaked at $212K in Q3 2022. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Two Sigma Securities reported no remaining ADMA Biologics position as of Q2 2026 after selling out during the quarter.
Two Sigma Securities sold 16,994 ADMA Biologics shares in Q2 2026, an estimated $153K.
Two Sigma Securities first reported a position in ADMA Biologics in Q4 2021 and held it in 8 quarters.
Two Sigma Securities's ADMA Biologics position peaked at $212K in Q3 2022.
322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Two Sigma Securities's 13F filing for Q2 2026, filed 14 Aug 2026.